BCL2 and acute myeloid leukemia: Mutations in genes encoding the isocitrate dehydrogenase isoforms 1 and 2 (IDH1, IDH2) are found in approximately 15% of AML patients [78] and have been shown to confer exquisite susceptibility to BCL-2 inhibition via cytochrome C oxidase inhibition mediated by the oncometabolite 2-hydroxyglutarate, ultimately resulting in the lowering of the mitochondrial threshold for the triggering of apoptosis [79].